I told you so

This stock jumped 63% *this morning* ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ *Sponsored by RagingBull. Please see disclosures below. Dear Trader , This morning, I briefed you on a little-known nano-cap stock in the biotech sector that I believed was preparing to swing rapidly towards the upside — That company is Hillstream BioPharma (NASDAQ: HILS) and sure enough… They came charging out of the gate this morning, opening 63% higher than yesterday’s close. Even after a mild shakeout, it’s still up 32% for the day as of this writing. As I pointed out in this morning’s message (copied below in case you missed it), this type of move is not unusual for this company. And here’s the thing… We’re still in the early innings. There’s room for plenty of upside movement on HILS. With the company committed to seeking FDA approval for clinical trials in the first half of 2023… It’s barrelling towards a series of impressive milestones capable of sending the stock into even higher territory. Considering the fact that we saw it leap 63% just this morning, you can imagine what sort of moves are possible on good news from the FDA. In short, I don’t think we’ve seen the end of Hillstream BioPharma’s run, and I’m incredibly bullish on the stock. Scroll down to look over my analysis on the company, or [click right here]( )[to get the full story]( ). - Corey With all eyes firmly fixed on First Republic (FRC) and Big Tech this week… (Not to mention all the media chatter surrounding Tucker Carlson and Bud Light)... You probably overlooked this biotech gem — [Hillstream BioPharma, Inc. (Nasdaq: HILS)]( ) While the overall tech sector is roaring out of the gate with killer earnings, this little-known biotech firm which had their IPO last year at $4.00 — now priced at a paltry $0.71 — is set to carve out its stake. After months of choppy, sideways action… It’s refreshing to come across a stock like this — At first glance, HILS captured my attention as the sort of rare "nano-cap" gem that I like to get my hands on… And after fully digging into the company… I’m pleased to report that I was exactly right. It’s got everything — From market positioning… to the technicals… to the board and their roadmap… This is one of those hidden stocks that you should have on your radar, immediately. So without any further ado, let’s dig in and see what makes this stock so special. First off, we’ve got: 1) Niche Market Domination HILS is filling a CRITICAL void in the biotech market Right now, oncology — the study and treatment of cancers — is a $283.5 BILLION market… one that’s expected to hit $581 BILLION in revenue by 2028… That’s not surprising when you consider that a cure for cancer would be the supreme medical miracle… And the simple fact is: HILS is doing its part to make that possible. Now, I’m no doctor, so I’m not going to get too deep into the specifics here… [(Here’s the rundown from actual medical experts)]( ) But essentially what these folks are doing is developing a viable alternative to traditional chemotherapy. Let me put that into perspective for you. HILS is spearheading the type of radical shift that’s capable of completely redefining the industry — They’re working to do for medicine what Apple did for telecommunications… and we all know how that went. Or think about tiny Illumina, Inc (ILMN) which rewarded shareholders with an incredible breakout from less than $1 to well over $500 per share in a matter of years as they developed their cancer-detection technology. HILS’ therapeutics target solid tumors (which make up 90% of all cancer cases, and are notoriously difficult to treat) while reducing the likelihood of the nasty side effects. The value in that simply cannot be understated. If you’ve ever witnessed a loved one undergoing chemotherapy — myself and many of my colleagues can attest — It’s not a pretty picture. It’s been accurately described as a treatment that kills the cancer slightly faster than it kills you… and that’s the best case scenario. Rather than blasting folks with heavy doses of radiation and chemicals, HILS has developed what they call a "Quatramer." It’s a seek-and-destroy mechanism that delivers cancer-treating drugs directly to the tumor. We’re talking about a technology with the potential to bring us much closer to a true cancer cure… [You can click this link here to see exactly how it works.]( ) 2) Sound Technicals & Insider Confidence Confident insider holdings, low market cap, and a history of parabolic jumps are showing hot and heavy upside potential As of this writing, HILS is sitting on a market cap of just $9.51 million, making it a true "nano-cap" company. Meaning that even relatively small upticks in demand have the potential to send it soaring. As an added bonus, the upside potential is magnified by the fact that so much of the company is privately held. Right now company insiders are holding about 57% of shares, demonstrating high levels of confidence — Which is a SHINING endorsement coming from a board that’s stacked with executives from biotech titans like DuPont, Merck, and even the founder and chairman of the Global Cancer Research Institute. We’re looking at an all-star roster leading this project, and all it takes is a quick look at their balance sheet to see why they’re not hesitating to eat their own cooking: Their debt-to-asset ratio is very low, indicating that today’s price of $0.71 is looking like a rock-solid springboard… And with only 3.56M shares available to the public, this low-float stock has the potential for dramatic upswings… Such a small liquidity pool has allowed relatively small bouts of buying pressure to send the stock skyrocketing by as much as 661% in less than two months. That wasn’t ancient history, either — It was happening just a few months ago: And that’s far from the only time it’s gone parabolic: [(Click here for more details)]( ) We’re looking at a stock that seems to routinely jump by 60%... 70%... even 189% in just a few days… While we can’t ever depend on the past to repeat itself, I’m anxiously anticipating that HILS will soon make one of the fast-charging moves higher that it has shown us over the past few months. Which brings me to the MOST important factor I’m looking for in a short-term idea… 3) HUGE Forward Momentum HILS proved itself in an early compassionate-use study in Germany, where the active ingredient in its premier drug showed efficacy on difficult-to-treat cancers including triple-negative breast cancer and epithelial carcinomas. And now… HILS is courting the FDA as early as June to authorize human drug trials. I don’t think I need to tell you how massive this kind of news is for a biotech company. This is the biotech equivalent of Hillstream BioPharma getting called up from the minors to pitch for the New York Yankees. We’ve seen the headlines time and time again: Like when AstraZeneca launched their clinical trials for a COVID vaccine — Investors who jumped in before the trial went live were capable of snatching up a 55% gain — in just three months. They say history doesn’t always repeat itself, but it often rhymes… And given the fact we’ve witnessed this same story play out like clockwork over the years… Receiving the trial authorization is just the tip of the iceberg. Once those trials are in motion, a steady stream of success is capable of sending this stock into overdrive, potentially eclipsing even the 661% gain we saw earlier this year. Frankly, I could go on about this stock all day — We’ve got: - Niche market dominance ✔ - Sound technicals ✔ - A history of lightning-fast profits ✔ - Strong insider holdings (over 50%!) ✔ - And a MAJOR industry milestone just around the corner ✔ I mean, a stock with even a few of these factors is always worth taking a look… But this stock is ticking every box, and all for less than a cup of coffee! Ultimately making HILS the type of rare gem that’s capable of delivering massive gains, even in a choppy market like the one we’ve been sitting through for the last few months. Meaning it would be downright irresponsible of you, as a trader, to gloss over Hillstream BioPharma (NASDAQ: HILS) without at least clicking here to get the full rundown on the company right now. I hope you love this stock as much as I do, but I always want to encourage you to do your own research and make sure that you are comfortable with the risks, and also the potential upside with this explosive idea. A great place to start is by [visiting this]( )[website]( ). Have a great day of trading, and I will be back soon with further updates. *Please see disclosures below. Regards, Corey Snyder Publisher, Rogue Investing *PAID ADVERTISEMENT. Rogue Publishing has been paid five thousand dollars by ach bank transfer by RagingBull for advertising Hillstream BioPharma from a period beginning on April 27, 2023 through April 28 of the same year. As a result of this advertisement and other marketing efforts, Rogue Publishing may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of Rogue Publishing do not hold a position in Hillstream BioPharma. This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Hillstream BioPharma, increased trading volume, and possibly an increased share price of the Hillstream BioPharma securities, which may or may not be temporary and decrease once the marketing arrangement has ended. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Rogue Publishing can guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of Rogue Publishing’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Rogue Publishing, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as "believes," "anticipates," "estimates," "expects," "projects," "intends," or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Rogue Publishing does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at [( ) TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. Sent to: {EMAIL} [Unsubscribe]( ) Rogue Investing, 721 Court St., Unit #1, Lynchburg, VA 24504, United States